Trials / Completed
CompletedNCT00047736
A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung Cancer
A Phase III, Randomized, Double Blind, Multicenter Trial of Tarceva (Erlotinib) Plus Chemotherapy (Carboplatin and Paclitaxel) Versus Chemotherapy Alone in Patients With Advanced (Stage IIIb or IV) Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if Tarceva plus standard chemotherapy is more effective than standard chemotherapy alone in the treatment of lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tarceva (erlotinib HCl) |
Timeline
- Start date
- 2001-07-01
- Completion
- 2003-07-01
- First posted
- 2002-10-17
- Last updated
- 2013-06-21
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00047736. Inclusion in this directory is not an endorsement.